|Bid||135.3800 x 400|
|Ask||135.4100 x 300|
|Day's Range||135.1400 - 136.2700|
|52 Week Range||109.3200 - 137.0800|
|PE Ratio (TTM)||22.77|
|Dividend & Yield||3.36 (2.49%)|
|1y Target Est||N/A|
The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
Johnson & Johnson (JNJ:NYSE) By Credit Suisse ($134.46, July 20, 2016) We are reinstating coverage of Johnson & Johnson with an Outperform rating and $148 target price. The stock has appreciated about 20% since the deal was announced on Jan. 26 (versus the S&P 500 up 7.5%) but we see room for further upside, driven by key pharma growth drivers. Based on channel checks and detailed modeling we have done across various therapeutic areas, we see opportunities for significant upside from assets such as Xarelto, Darzalex and Imbruvica.